DS

David Schenkein

General Partner at GV

Boston, Massachusetts

Overview

Work Experience

G

GV

  • General Partner

    2019 - Current

R

Regeneron

  • Board Member

    2023

TM

Tufts Medical Center

  • Clinical Professor of Medicine

    2009

AP

Agios Pharmaceuticals

  • Board Member

    2022

  • Chairperson of the Board

    2019 - 2022

  • CEO

    2009 - 2019

DT

Denali Therapeutics

  • Board Member

    2015

G

Genentech

  • Senior Vice President, Clinical Hematology/Oncology

    2006 - 2009

Millennium Pharmaceuticals

  • Senior Vice President, Clinical Research

    2001 - 2006

Education

Investments

Delphia Therapeutics

Series A

Total Funding: $67M

Cerevance

Series B

Total Funding: $160M

EpiBiologics

Series A

Total Funding: $96M

Aera Therapeutics

Series B

Total Funding: $190M

Relevant Websites